APR 2 9 2002 2



#16/X.T. 5/18 Scippi.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1.4.5.

In re Application of: Andrew S. Greenberg

Application No: 09/690,647

Filed: October 17, 2000

For:

Methods for Treating and Preventing

Insulin Resistance and Related

Disorders

Examiner: Schmidt, M.

Art Unit:

1635

Attorney Ref. No: TUV-005.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on April 18, 2002.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Assistant Commissioner for Patents Washington, DC 20231

95/21.2002 SCEAPIEL 10061110 01.448 | 09890847 08 FT:180 | 180100 0

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 CFR 1.56. Copies of these documents ("EA" - "EF") are also being submitted herewith.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the

application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of said document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

As a First Office Action on the merits has been received, please charge the applicable amount due of \$180.00 as required under 37 C.F.R. § 1.17(p) to our **Deposit Account No. 06-1448**.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Date: April 18, 2002

Customer No. 25181

Patent Group

Foley, Hoag & Eliot LLP One Post Office Square

Boston, MA 02109-2170

Respectfully Submitted,

Isabelle M. Clauss, Ph.D.

Reg. No. 47,326

Attorney for Applicant

		N DISCLOSURE CITA N APPLICATION	6	Docket Number (Optional) TUV-005 01 Applicant	Application Number 09/690,647					
		reral sheets (necessary)		Andrew S. Greenberg Filing Date 10/17/00			Group Art Unit 1635			
	_	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	- 40				<u>, </u>			
EXAMINER INITIAL)rMAN DATI	E NAMI	E CI	CLASS			FILING DATE IF APPROPRIATE	
	T	····		FOREIGN PATENT I	DOCUMENTS			T 1		
	I.	OCUMENT NUMBER	DATE	COUNT	RY C1	CLASS		Translation YES NO		
&	-									
	1_									
Start And Months									-	
3 5 /	-									
		OTH	IED DO	CUMENTS	(1)	J: 4. 4J	Tul D . B		<u> </u>	
	-	Engelman et al. (2000), Ti	osis Factor α-Mediated Insulin	Resistance, but Not Dediffer		r, Title, Date, Pert s Abrogated by Mi				
٠,	EA	3T3-L1 Adipocytes, MOLECULAR ENDOCRINOLOGY 14(10):1557.								
	EB	1 DIOL CUEM 373/30\.34/75								
	EC	Edelstein Rosenbaum and Greenberg (1998), The Short- and Long-Term Effects of Tumor Necrosis Factor-α and BRL 49653 on Peroxisome Proliferator-Activated Receptor (PPAR) 12 Gene Expression and Other Adipocyte Genes, MOLECULAR ENDOCRINOLOGY 12(8):1150.								
	ED	Greenberg et al. (1993), Isolation of cDNAs for Perilipins A and B: Sequence and Expression of Lipid Droplet-Associated Proteins of Adipocytes, PROC. NATL. ACAD SCI. USA 90:12035.								
	EE	Egan et al. (1992), Mechanism of Hormone-Stimulated Lipolysis in Adipocytes: Translocation of Hormone-Sensitive Lipase to the Lipid Storage Droplet, PROC. NATL. ACAD. SCI. USA 89:8537.								
	EF	Camp et al. (1999), c-Jun N-Terminal Kinase Phosphorylates Peroxisome Proliferator-Activated Receptor-Yl and Negatively Regulates its Transcriptional Activity, ENDOCRINOLOGY 140(1):392.								
										
							, , , , <u> </u>			